IXCHIQ Chikungunya Vaccine Trial Shows Sustained Immune Response in Adolescents
Автор: Xtalks
Загружено: 2025-01-22
Просмотров: 218
Описание:
Read more: https://xtalks.com/ixchiq-chikungunya...
Valneva SE, who developed the world’s first FDA-approved chikungunya vaccine, has now unveiled promising Phase III data for its single-shot chikungunya vaccine, IXCHIQ, in adolescents aged 12 to 17. Following the announcement, Valneva’s stock rose by 1.4%.
IXCHIQ is the only licensed chikungunya vaccine in the US for adults aged 18 and older at increased risk of exposure to the virus.
#shorts
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке: